Next Phase Newsletter

The venture fund is a healthcare investment firm founded in 1992 with offices in Massachusetts and California. The company actively finds and invests in life sciences companies (both public and private) that seek to cure major diseases by translating scientific innovations into positive clinical outcomes. With $1.5 billion in assets under management, the firm typically makes investments ranging from $3 to $25 million depending on the target company’s stage of development and capital requirements. The firm considers investments into companies located anywhere around the globe.

The firm invests in breakthrough therapeutics, with a focus on oncology. However, the firm also considers investments into companies developing platform technologies. While the firm considers

investment from seed stage to private investment in public equity, the firm’s ideal company has an asset that is pre-clinical or in early clinical trials.

The firm invests primarily in private companies but will also consider private investment in public equity opportunities.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

The firm is a multinational biopharmaceutical corporation. The firm develops and produces medicines, vaccines and consumer health care products. The firm looks to invest in/partner with academic research and start-up companies for developing innovative therapies and delivering value to the company. The firm has established a number of partnering models including Academic & Start-Up Company Partnerships, Alternative Development / Funding Models, Centers for Therapeutic Innovation, Global Scouting, Open Innovation Portal and a Corporate Venture Fund. The firm also takes part in equity rounds, usually with rights attached. The company is open to make co-development deals to help early-stage biotech companies, and is currently looking for new investment opportunities across the globe with a focus in North America, Europe, and Asia.c

The firm is currently looking for innovative therapeutics and medical technologies targeting the following areas: Cardiovascular & Metabolic Diseases, Immunology & Inflammation, Neuroscience, Oncology (including Immuno-Oncology), Rare Diseases (Gene Therapy as a platform), and Vaccines. In neuroscience, the firm is focused on neurodegenerative diseases, particularly technology in Alzheimer’s and Parkinson’s disease, and is open to preclinical (conception) to Ph III technology in this strategy. Neuroscience companies in neuroinflammation (i.e. microglia) and other emerging CNS areas, including CNS rare diseases and symptom-treating technology, require robust Ph II (or beyond) data. For rare indications, the firm requires a therapeutic approach that directly addresses the genetic cause of the disease. The firm is also open to other life science technologies that may speed up the development process, including lab technology and drug development enabling technologies. The firm also seeks in-licensing products for development. Overall, the firm is open to all stages of development, as the firm has separate teams to encompass all phases of development from preclinical to commercial stages.

The firm collaborates – in multiple formats – with both privately held and public life science companies with experienced management teams, innovative technologies, and an established scientific unit.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

The corporate venture arm of a big pharma is a diversified business based in Tokyo focused on three primary sectors: Materials, Homes and Healthcare. The team is based in offices outside Boston, MA and Menlo Park, CA. The fund has an evergreen structure looking to allocate between $1-$3 million per deal initially and up to $5 million over the life of the investment. The firm is seeking to invest in approximately 2-4 companies over the next 12 months and is open to investing in companies across the globe.

Sectors of interest include: pharmaceuticals, medical devices and digital health. Therapeutic and product areas of interest include: Pain, critical care, musculoskeletal disease, kidney disease, DDS, patient monitoring technologies, bioprocessing technologies, digital therapeutics. The firm is open to all stages of investment, with a general preference toward companies with at least some early clinical data.

The firm invests in private companies and is willing to work with all types of management teams including incomplete teams. The firm generally requests at least an observer seat following investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

A San Francisco based Venture Capital firm founded in 2016 is focused on early-stage healthcare companies. The firm currently has 29 companies in their portfolio, and has a network of family offices and high net worth individuals the firm shares deal flow with. The firm invests in all 4 life science sectors and the typical check size ranges from $100K – 500K in the form of equity or convertible notes. The firm generally seeks to make investments into emerging life science companies in Pre-Seed, Seed and Series A stages. The firm is US-focused in terms of geographic preference, but will occasionally look outside of the US.

The firm invests across all life science verticals and is open to all 4 sectors. The firm looks for novel technologies in biotech, medtech, digital health therapeutics, and diagnostics. In terms of biotech companies, the firm focuses on biotechnology platforms rather than single asset biotech companies. The firm is agnostic to both subsector and indication, and is open to both pre-clinical therapeutic companies as well as all three stages of medical devices.

The firm is open to all types of management teams, with a goal to democratize who gets funding in the life science space. The firm is looking for diversity in the management team to combine ideas and skill set. Bioverge prefers to co-invest rather than lead.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

The healthcare-focused arm of a family office based in Boca Raton, FL is interested in global companies but is currently more focused on the US, Canada, Europe, and Israel regions. The firm makes investments ranging from $5 – $80 million. The firm is open to both leading and co-investing. The firm prefers investing in companies that have demonstrated clinical data and is currently not limited in the number of investments they plan to make this year.

The firm is interested in therapeutics, medical devices, and diagnostics. The firm is agnostic to the types of therapeutics, devices, and diagnostics they look to invest in. The firm is most interested in highly differentiable products that address unmet medical needs. Current portfolio companies include companies involved in cancer care, neurostimulation device, and cardiology device companies.

The firm looks for experienced management teams and depending on the deal, may or may not seek a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

A healthcare focused fund is headquartered in Shanghai and has presence in US and Europe. The fund has strong preference for early stage opportunities. The senior team members have strong operating experience in biotech and pharma companies, the firm has a strong preference to lead investments and play active contribute to the success in our portfolio companies.

The firm is particularly keen on cardiovascular, regenerative medicine, CNS and hearing related opportunities. The firm is otherwise agnostic in regards to specific disease indications and is willing to look at all early-stage opportunities, however, diagnostics is currently considered as a low priority.

As the firm seeks to be an active lead investor, the firm strongly prefers a board seat in companies. Outside of the board requirement, the firm is looking for a strong management team with passion and capability in advancing the company’s technology.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

A strategic venture capital arm and innovation group of, a large health system with 13 hospitals in Michigan and Ohio is managing both a seed fund as well as a later-stage corporate venture fund, both dedicated to medtech and healthcare IT. In addition, the group also has an incubator and innovation group that looks to develop and integrate IP generated internally and externally that can be leveraged by the health system. Seed investments usually range from $100k – $500k with additional capital reserved for follow on investments, typically allocating up to $1.5M over the life of the investment. Later stage investments are usually in the range of $1M-$2M. The group is flexible in terms of structure but typically refers to convertible notes for seed deals and straight equity for later-stage investments. The firm may lead investments or invest with a syndicate and looks to be active in portfolio companies’ development and add value at the board level as well as through integration into the health system.

The firm is exclusively focused on the medtech and digital health/healthcare IT sectors. The group is fairly opportunistic in these areas, but looks for technologies that can be leveraged by the health system. Both pre-revenue and pre-FDA approval devices, as well as commercial/revenue-generating companies, will be considered. ProMedica has no preference for regulatory pathway and has a particular interest in the cardio space.

The firm has historically focused on startups in the midwestern United States, however, is looking more broadly and open to companies across the U.S. The group favors strong management teams that are open to working closely together.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.